Horizon Pharma plc to Participate in Investor Conferences in November

DUBLIN, Ireland, Nov. 04, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that the company will participate at the following conferences in November:

Global Mizuho Investment Conference

  • Date: November 14, 2016
  • Location: New York, NY

Stifel Healthcare Conference

  • Date: November 15, 2016
  • Presentation Time: 8:45 a.m. EST
  • Location: New York, NY

Jefferies Autumn 2016 Global Healthcare Conference

  • Date: November 17, 2016
  • Presentation Time: 1:20 p.m. GMT
  • Location: London, United Kingdom

Bank of America Leveraged Finance Conference

  • Date: November 29, 2016
  • Presentation Time: 7:30 a.m. EST
  • Location: Miami, FL

Piper Jaffray Healthcare Conference

  • Date: November 29, 2016
  • Presentation Time: 8 a.m. EST
  • Location: New York, NY

For the above conferences with presentations, they will be webcast live and may be accessed by visiting Horizon's website at http://ir.horizon-pharma.com. A replay of the webcasts will be available for the events with presentations.

About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. Horizon Pharma markets 11 medicines through its orphan, rheumatology and primary care business units. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.

Contacts: Tina Ventura Senior Vice President, Investor Relations investor-relations@horizonpharma.com U.S. Media: Geoff Curtis Senior Vice President, Corporate Communications media@horizonpharma.com Ireland Media: Ray Gordon Gordon MRM ray@gordonmrm.ie

Source: Horizon Pharma plc